Expertise in
12
conditions

Dr. Anne C. Chiang

Oncology
Yale New Haven Hospital
20 York St, 
New Haven, CT 
Offers Telehealth
Expertise in
12
conditions
Yale New Haven Hospital
20 York St, 
New Haven, CT 

Overview

Anne Chiang is an Oncologist practicing medicine in New Haven, Connecticut.

Dr. Chiang is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma.

She is actively involved in clinical research, co-authoring 69 peer reviewed articles and participating in 7 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in CT

Hospital Affiliations

Yale-New Haven Hospital
Bridgeport Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Yale New Haven Hospital
20 York St, New Haven, CT 06510

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy
A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Drug
Study Drug: Ipilimumab+Nivolumab
Study Phase: Phase 2
A Window Study to Assess the Activity of Demethylation Therapy in Patients With HPV-Positive Compared With HPV-Negative Head and Neck Squamous Cell Carcinoma, With Response Assessment and Biomarker Expansion Cohort in HPV-Positive Oropharynx Cancer
A Window Study to Assess the Activity of Demethylation Therapy in Patients With HPV-Positive Compared With HPV-Negative Head and Neck Squamous Cell Carcinoma, With Response Assessment and Biomarker Expansion Cohort in HPV-Positive Oropharynx Cancer
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug
Study Drug: 5-Azacitadine
Study Phase: Phase 1
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases
A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases
Enrollment Status: Completed
Publish Date: March 24, 2021
Intervention Type: Drug
Study Phase: Phase 2
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

69 Total Publications

Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
Journal: Nature medicine
Published: June 29, 2026
Similar Doctors
Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Smilow Cancer Hospital

35 Park St, 
New Haven, CT 
 (0.1 miles away)
203-200-5864
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Gettinger is an Oncologist practicing medicine in New Haven, Connecticut. Dr. Gettinger is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-785-7385
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elena Ratner is an Oncologist practicing medicine in New Haven, Connecticut. Dr. Ratner is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, Salpingo-Oophorectomy, and Vaginectomy.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Yale University School Of Medicine

333 Cedar St, 
New Haven, CT 
 (0.1 miles away)
203-785-3597
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Petrylak is an Oncologist practicing medicine in New Haven, Connecticut. Dr. Petrylak is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Urothelial Cancer, Familial Prostate Cancer, Orchiectomy, and Gamma Knife Radiosurgery.

Frequently Asked Questions about Dr. Anne C. Chiang

How do I make an appointment with Dr. Anne C. Chiang?

You can book an appointment with Dr. Anne C. Chiang by calling their office at 203-200-5864. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anne C. Chiang a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anne C. Chiang is classified as an Elite expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anne C. Chiang specialize in?

While Dr. Anne C. Chiang is a Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Anne C. Chiang participate in research or clinical trials?

Yes. Dr. Anne C. Chiang has published 69 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Anne C. Chiang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anne C. Chiang accept my insurance?

Dr. Anne C. Chiang accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 203-200-5864 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chiang's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile